Ctrl

K

Cabazitaxel

Class
Antimetabolites
Subclass
Mitotic inhibitors
Substance name
Cabazitaxel
Brand names
Jevtana®
Common formulations
Kit
Dosage and administration
Adults patients
Treatment of prostate cancer • Castration-resistant, metastatic
•
20 mg/m² IV q3 weeks
Indications for use
Labeled indications
Adults
•
Treatment of prostate cancer (castration-resistant, metastatic)
Safety risks
Contraindications
Previous severe hypersensitivity reactions to cabazitaxel
Warnings and precautions
ARDS
•
Use caution underlying or chronic lung disease.
Gastrointestinal bleeding
•
Use caution an active gastrointestinal disorder.
Gastrointestinal discomfort
•
Use caution prior radiation therapy.
Severe chronic neutropenia
•
Use caution a hemoglobin less than 10 g/dL.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required. Monitor serum creatinine. Serum creatinine should be measured at baseline, with each blood count and whenever the patient reports a change in urine output No studies have been done in haemodialysis patients so the company advises to monitor closely and use with caution.
Renal replacement therapy
Any modality
•
Use with extreme caution. Monitor serum creatinine.
Hepatic impairment
Child-Pugh A (mild)
•
Reduce dose. Start at dose of 20 mg/m² IV. Monitor serum aminotransferases.
Child-Pugh B (moderate)
•
Reduce dose. Start at dose of 15 mg/m² IV. Monitor serum aminotransferases. Monitor for toxicity.
Child-Pugh C (severe)
•
Do not use.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: D
•
Not intended for use in females. Evidence of fetal harm in humans. This drug is not indicated for use in females.
•
This drug can cause fetal harm and loss of pregnancy.
•
Men should use effective contraception throughout treatment and for up to 6 months after the last dose.
•
Due to potential exposure via seminal liquid, men should prevent contact with the ejaculate by another person throughout treatment.
•
If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Anemia, ↓ WBC count, ↓ blood lymphocyte count, ↓ blood neutrophil count
Common 1-10%
•
Bone fracture, ↓ platelet count, ↓ serum potassium, dehydration, hypertension, hypotension, ↑ liver enzymes, ↑ serum TBIL, pulmonary embolism, peripheral edema, peripheral neuropathy, renal failure, abdominal pain, arthralgia, asthenia, back pain, bone pain, constipation, cough, diarrhea, dizziness, dysgeusia, dyspepsia, dyspnea, fatigue, fever, hair loss, hematuria, insomnia, loss of appetite, muscle cramps, musculoskeletal pain, nausea, paresthesia, vomiting, spinal cord compression
Uncommon < 1%
•
Dysuria, headache, weight loss, stomatitis
Unknown frequency
•
AF, AV block, atrial flutter, bradycardia, bronchospasm, gastritis, gastroesophageal reflux, HF, hypertensive crisis, ILD, ileus, infusion-related reactions, lethargy, pancytopenia, pancytopenia, pneumonitis, malaise, myalgia, nocturia, urinary incontinence, urinary retention, skin erythema, supraventricular arrhythmia, VF
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource